Ironwood Pharmaceuticals, Inc. — Q3 2011 Form 10-Q
Reporting period: Three and nine months ended September 30, 2011; filed November 9, 2011. Financial statements are unaudited. Amounts below are in millions of dollars unless stated otherwise.
Business context
Ironwood is a development-stage pharmaceutical company with no product sales to date. Its lead candidate, linaclotide, is being developed for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The company shares U.S. development costs and potential profits and losses with Forest, and has regional licensing partners Almirall and Astellas. It sold its Microbia biomanufacturing subsidiary in 2010; comparative discontinued-operations results therefore affect year-over-year comparisons.
Financial performance and liquidity
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Collaborative arrangements revenue | $12.2 | $9.1 | $33.7 | $27.1 |
| Research and development expense | $22.9 | $18.7 | $61.9 | $56.2 |
| General and administrative expense | $10.9 | $6.5 | $31.0 | $18.9 |
| Operating loss | $(21.6) | $(16.2) | $(59.1) | $(48.0) |
| Net loss attributable to Ironwood | $(20.6) | $(8.3) | $(57.9) | $(41.3) |
| Basic and diluted loss per share | $(0.21) | $(0.08) | $(0.58) | $(0.48) |
- Revenue increased 34.9% in Q3 and 24.5% in the first nine months. Growth primarily reflected Almirall milestone-related revenue, including revenue recognized from its 2010 milestone payment and a revised estimate of the development period.
- Operating expenses rose 34.1% in Q3 and 23.7% for the nine months. R&D increases included personnel, external research and preclinical programs; G&A increases reflected headcount, facilities, and preparations to commercialize linaclotide.
- Q3 2010 net loss included $6.4 million of income from discontinued operations and a $2.9 million income tax benefit from continuing operations; this limits direct comparison with 2011.
- Cash and cash equivalents were $68.8 million at September 30, 2011, and available-for-sale securities were $106.3 million. Unrestricted cash, equivalents and securities totaled approximately $175.1 million, versus $248.0 million at December 31, 2010.
- For the nine months, operating cash use was $67.5 million, investing activities provided $89.5 million (mainly net securities maturities and sales), and financing activities provided $2.5 million. Cash and cash equivalents increased $24.5 million to $68.8 million.
- Total assets were $219.5 million; current assets were $178.8 million and current liabilities $70.8 million. The filing reports capital lease obligations of approximately $0.7 million in total. Deferred revenue was $69.6 million, including current and long-term portions.
- Ironwood had an accumulated deficit of $425.4 million and expects continued losses. It reported no product revenue or commercial profitability.
Material changes and notable items
- On October 24, 2011, after quarter-end, the FDA accepted the linaclotide NDA for IBS-C and CC for review. The filing states an expected PDUFA target action date of June 2012.
- FDA acceptance triggered $20.0 million in pre-commercial milestone payments from Forest, expected to increase collaborative revenue in Q4 2011.
- Almirall submitted an EU marketing application for linaclotide for IBS-C in September 2011. The company reported positive results in all four Phase 3 trials: two IBS-C and two CC.
- Ironwood recognized $0.9 million of other income in Q3 from a Massachusetts life-sciences tax incentive grant. The company said it believed it had met the job commitments; the award may be recoverable if commitments are not maintained.
- In June 2011, Ironwood shortened its estimated Almirall development period from 50 to 41 months, accelerating recognition of deferred revenue. Adoption of new revenue-recognition standards had no material impact on reported results, though the milestone method may affect future periods.
Outlook, risks and commitments
- Management said available resources and potential collaborator milestone payments were expected to support projected operating needs through anticipated linaclotide commercialization, while cautioning that forecasts are uncertain and actual cash use could be faster. Additional financing or program reductions could be needed if assumptions change.
- Management expected continued substantial R&D spending and increasing G&A as the company advances its pipeline and prepares for potential commercialization. Revenue may fluctuate with milestone timing; the company cannot yet estimate precisely the cost or timing of regulatory approval or future product revenues.
- Key risks include FDA or foreign regulatory delay, denial or restricted labeling; safety and market-acceptance concerns; manufacturing capacity, quality and supply risks; dependence on partners; competition and reimbursement/pricing pressure; and the need for additional capital. Diarrhea was the most common adverse event in linaclotide Phase 3 trials, reported in 14%–20% of treated patients; 3%–6% discontinued because of it.
- Minimum linaclotide supply purchase commitments were approximately $45.0 million through 2017, with the earliest commitments beginning in 2012. The company also disclosed a subsequent October 2011 lease amendment for additional office/lab space, with rent beginning no later than June 2012.
- Management concluded disclosure controls were effective at a reasonable assurance level and reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and outcome of FDA review, including the expected June 2012 action date, and the status of the European application.
- Timing and receipt of the $20.0 million Forest milestone, and the terms and timing of remaining partner milestones and royalties.
- Cash runway assumptions against ongoing losses, commercialization spending, and the $45.0 million supply commitments.
- Commercial-scale manufacturing readiness, partner execution, and the implications of linaclotide’s reported diarrhea rates for labeling and adoption.
- Whether the Massachusetts grant’s job-maintenance conditions remain satisfied and whether any repayment exposure arises.